Olivia Vizier

An anti-CD70 antibody-drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70, according to the company.

In this video from ASN Kidney Week, Jonathan Barratt, MBChB, PhD, discusses Calliditas Therapeutics’ Tarpeyo treatment, previously known as Nefecon, for patients with IgA nephropathy.

TFF Pharmaceuticals is advancing this technique as a platform technology for improving the formulation of complex modalities, including vaccines, small molecules and biologics, as dry powders. According to Hannon, this approach provides key advantages, including access to more convenient routes of administration due to aerosolization properties (i.e., inhalation or intranasal delivery) and elimination of the

The Thin Film Freezing technology, invented by Dr. Williams and his team and advanced by Fort Worth-based TFF Pharmaceuticals, is developed via a well controlled process that involves rapid freezing and drying drugs into a powder.

MIT-born startup Elicio Therapeutics’ novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads.

Fungal infections kill more than 1.6 million people yearly, according to Global Action for Fungal Infections, a research and fundraising organization. The toll is climbing. Fungi are adapting to rising temperatures in ways that may make them better suited to thrive in the human body, researchers said. And more people undergoing treatments that weaken their

Ring Therapeutics, have revealed 60 open reading frame 1 (ORF1) protein fragments that feature a modified jelly-roll–domain core architecture, with residues that extend from the surface to

One such method is based on ImmTOR nanoparticles (Selecta Biosciences), which leverage rapamycin to generate antigen-specific immune tolerance (Figure 1). The nanoparticles are designed to accumulate in the spleen and liver

Dr. Diem Nguyen,  the CEO of Xalud Therapeutics, talks about Xalud’s work to reduce the inflammation that drives pain. It’s now in human clinical trials.

SOTIO, for example – an international biotech originating from the Czech Republic – focuses on immuno-oncology and developing innovative methods for treating cancer. The company has been conducting multiple Phase I to III clinical trials, and uniquely uses four distinct technological platforms, which each include multiple promising drug candidates.

Yochi Slonim, M.Sc., co-founder and CEO of Anima Biotech, explained the rationale for building a platform technology company in Israel.

Our plan to achieve sustainability as a business practice in the coming years lies within Calliditas’ strategy to execute on our vision to efficiently expand, develop, and market our pipeline of innovative medicines targeting rare diseases that have the potential to improve the lives of patients with

At Xalud, we’re developing a non-viral plasmid DNA platform that has the potential to change the paradigm in chronic inflammatory diseases by creating a gene therapy for the masses and not just for rare diseases. We have a pipeline with broad potential for our proprietary platform, including several programs in development, and we look forward

But in 2019, he walked away from all of that to become the founder and CEO of Alto Neuroscience, which the company said is “pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.”

Teclison has developed platform technology that chokes off tumors and activates the immune system against the cancer.

That’s why Yoav Kimchy, Founder and CTO of Check-Cap, launched the company in 2005 with the goal of creating a technology that could make colorectal screenings easier and less invasive for patients.

“We’ve hit the wall in terms of how much more we can leverage an antibody,” says David Apelian, MD, PhD. As the CEO of BlueSphere Bio, Apelian is more than willing to consider alternatives to antibodies. Indeed, BlueSphere is interested in developing therapies that rely on T-cell receptors (TCRs). The company is already using TCR

Araris Biotech AG secured $24 million in financing to advance the development of its proprietary antibody-drug conjugate-linker technology and drive its own ADC candidates into the clinic.

IMV is evaluating DPX-based assets in several clinical trials in difficult-to-treat cancer indications, including diffuse large B-cell lymphoma (DLBCL), ovarian, breast, and bladder cancer. Previous studies have shown encouraging results, notably in pa­tients who have failed on prior lines of therapy. MVP-S is the clinical validation and proof of concept of the DPX platform’s potential

“Continued innovation in both conventional and next-generation protein therapeutics, cell and gene therapies, RNA- and DNA-based treatments, and vaccine technologies is driving demand for fill/finish capacity,” says Ping-Yang Yeh, president of AltruBio Taiwan, a subsidiary of AltruBio, Inc.

Mattes says there isn’t an official founding date for TFF Pharmaceuticals (NASDAQ TFFP) as the company sprung from another Austin-based organization known as Lung Therapeutics circa 2017.

A unique approach to pediatric glioma treatment comes from EMulate Therapeutics, a clinical-stage therapeutic device company. EMulate’s proprietary platform uses ultra-low radio frequency energy (ulRFE®) to record and replay a molecule’s digital fingerprint.

The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a bit of a misnomer. Although Earth abounds with pathogens that can maim, kill, paralyze, and poison, the specimens inside this machine — being pipetted left and right behind glass for sequencing — are probably the most innocuous human viruses you will ever

In another advance, IMV Inc. recently announced positive data in metastatic bladder cancer patients using its cancer vaccine, Maveropepimut-S (MVP-S) – also known as DPX-Survivac.

BlueSphere Bio presented a poster describing its TCXpress and iTCXpress high-through platforms for TCRs.

The day you’ve been waiting for has arrived. It’s time to meet the 2022 honorees of the BostInno Fire Awards.

What patients say they are feeling is also a possible source of confusion. Amit Etkin, the CEO of Alto Neuroscience, points out that in Asia the symptoms that Western psychiatry uses to diagnose depression—low moo

Michelle Mellion, M.D., newly-appointed SVP and head of clinical development at PepGen, began her career working to deliver the best possible to care to patients and education to medical students. Now she is working to ensure the patient’s voice is heard throughout the drug development process.

More than two years after Pfizer tied the knot with machine learning firm CytoReason in an AI-focused deal, the two companies have agreed to keep the partnership alive for at least five more years.

NEW YORK – Elicio Therapeutics said Tuesday that it received a $2.8 million grant from the Gastro-Intestinal Research Foundation in Chicago that it will use to develop two cancer vaccines.